Home/TechImmune/Jeffrey Ulmer, PhD
JU

Jeffrey Ulmer, PhD

Chief Executive Officer and Board Member

TechImmune

TechImmune Pipeline

DrugIndicationPhase
Long COVID ImmunotherapyTreatment of Long COVID / Post-Acute Sequelae of SARS-CoV-2 (PASC)Pre-clinical
Acute COVID-19 Antiviral TherapyTreatment of acute COVID-19, prevention of Long COVIDPre-clinical